PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 2633728
• 负责人: FAITH H KUNG
• 金额: $ 9.49万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-07-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2633728
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities.

该提案代表支持继续参与的请求 小儿肿瘤学组（POG）。这项合作研究是专门的 研究化学治疗，免疫和分子 急性白血病和其他治疗的生物学方法 童年的肿瘤疾病。 重要的无疾病生存具有 已实现并在临床药理学中做出了贡献， 癌症的肿瘤免疫学和生物学。 但是，真正的目标 这些研究是通过治疗消除肿瘤性疾病。 研究旨在反映攻击强度的增加 在肿瘤细胞上。 合作小组技术允许提示 一系列有希望的潜在客户的评估 化学疗法。这些线索或新方法经常由 该小组自己在临床肿瘤学方面的工作结果。 因此，一个完成 协议通常建议在新协议中探索新途径。 pog LED在急性淋巴细胞的免疫表型研究中进行了研究 白血病，NTX聚谷氨酸在白血病细胞和N-MYC中积累 神经母细胞瘤中的基因扩增，将发现与患者相关 结果，然后将它们纳入设计的新治疗方案中 改善癌症儿童的生存。 分裂 加利福尼亚大学圣地亚哥分校的儿科血液学/肿瘤学 合作有24年的经验（在Calgb工作10年，在POG中有14年） 临床试验。 在过去的5年中，4个财团会员 机构已进入332例治疗和非治疗患者 治疗研究和卫星，211名患者。 我们的调查人员 在12个委员会中任职，设计/协调16个小组协议研究。 我们还为15个小组出版物/演讲做出了贡献。 我们的 调查人员将继续设计和主席治疗方案，以及 在委员会任职。 Yu博士的实验室将继续探索新的 免疫治疗剂用于组使用，并作为小组参考 实验室。 我们计划继续积极参与各个阶段 POG活动。